Patients with relapsed CML, MM, or other diseases were treated with defined doses of CD8-depleted CD4+ T cells with clinical responses in ~80% of patients and GVHD developing in about one-third of patients [compared to a ~75% GVHD incidence with conventional DLI (46)]. This evidence concerns the gene CD4 and chronic myelogenous leukemia, BCR-ABL1 positive.